The High-Throughput Screening Core allows the rapid identification of biologically active chemical scaffolds from libraries containing several thousand discrete chemicals, and potentially containing naturally occurring ones obtained from natural sources such as plants. MSKCC has implemented the creation of a state of the art high throughput screening core facility with modern robotics, custom built screening data management databases for storing and querying data, and setting up strategic collaborations for the supply chemicals and to provide expertise in medicinal chemistry optimization. The facility contains a custom built six meter linear track robotic platform equipped with plate hotels, incubators for cell based assays, bulk liquid dispensers (Multidrops), 384/1536 liquid handlers (Apricot Designs TPS), a Perkin Elmer MicroBeta counter, two Perkin Elmer Victors multi-detection plates readers, two Molecular Device absorbance scanners, and one Amersham Multi-detection imager. Screening data acquisition and management is handled through custom built software named ORIS, which is composed of a chemical registration and inventory function together with an automated data loader for acquisition, analysis and screen data publishing. The compound library will grow to up to 500,000 discrete chemicals from selected commercial vendors and will also contain a wide variety of natural products, some purified and others in extract mixtures pending screening and dereplication to identify and purify the active product(s). The impact of such an infrastructure on the ongoing cancer research will be in the following areas: 1) Chemical cancer biology to discover novel control mechanisms to help further elucidate known or discover novel cancer pathways including control junctions, 2) Novel chemical scaffolds for use as radiotracers for biochemical and metabolic studies in vivo and for use in cancer diagnostics, and 3) the classical drug discovery process in which in vitro and/or cell based targets are screened and the resulting chemical hits are subjected to secondary and high content screens, in order to further optimize their chemical structures and their drug properties, and to show some efficacy against the specific cancer with little or no side effects, making them good drug candidates for the clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-47S4
Application #
8602884
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-01-20
Project End
2014-12-31
Budget Start
2012-01-09
Budget End
2012-12-31
Support Year
47
Fiscal Year
2013
Total Cost
$534,946
Indirect Cost
$252,801
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Meyer, Jan-Philip; Tully, Kathryn M; Jackson, James et al. (2018) Bioorthogonal Masking of Circulating Antibody-TCO Groups Using Tetrazine-Functionalized Dextran Polymers. Bioconjug Chem 29:538-545
McFarland, Daniel C; Shaffer, Kelly; Breitbart, William et al. (2018) C-reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer. Cancer :
Lacouture, Mario E; Anadkat, Milan; Jatoi, Aminah et al. (2018) Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. Clin Colorectal Cancer 17:85-96
Blumenthal, Gideon M; Bunn Jr, Paul A; Chaft, Jamie E et al. (2018) Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol 13:1818-1831
Shaffer, Kelly M; Nelson, Christian J; DuHamel, Katherine N (2018) Barriers to participation in a sexual health intervention for men following treatment for rectal and anal cancer. Psychooncology 27:1082-1085
Park, Kay J; Patel, Prusha; Linkov, Irina et al. (2018) Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy. Histopathology 72:766-776
Pianko, Matthew J; Goldberg, Aaron D; Lesokhin, Alexander M (2018) Clinical Development of PD-1 Blockade in Hematologic Malignancies. Cancer J 24:31-35
Navi, Babak B; Marshall, Randolph S; Bobrow, Dylan et al. (2018) Enoxaparin vs Aspirin in Patients With Cancer and Ischemic Stroke: The TEACH Pilot Randomized Clinical Trial. JAMA Neurol 75:379-381
Shah, Sona; Boucai, Laura (2018) Effect of Age on Response to Therapy and Mortality in Patients With Thyroid Cancer at High Risk of Recurrence. J Clin Endocrinol Metab 103:689-697
Goldman, Debra A; Hovinga, Koos; Reiner, Anne S et al. (2018) The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis. J Neurosurg :1-9

Showing the most recent 10 out of 8799 publications